Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Iovance Biotherapeutics (IOVA) stock in plain English

Free brief · no signupStart here
IOVAPublished Nov 17, 2026
Iovance Biotherapeutics Inc
Healthcare · Biotechnology
Manufactures and sells personalized cell therapies for advanced melanoma and other solid tumors.
Assets:
iVance CenterProprietary manufacturing facility located in Philadelphia, Pennsylvania.
AmtagviFirst FDA-approved tumor-infiltrating lymphocyte therapy for advanced melanoma.
Clinical pipelineActive trials testing cellular therapies for lung and head cancers.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

66
OPS ScoreOperating finances
Latest quote
-2.27%$7.31
$3.38B
n/a (loss)
$378.72M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 17, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was IOVA. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Iovance Biotherapeutics (IOVA) do?

Iovance Biotherapeutics Inc (IOVA) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Manufactures and sells personalized cell therapies for advanced melanoma and other solid tumors. Produces personalized cancer cell therapies extracted directly from each patient's own tumor tissue. It is worth $3.38B on the market and sold $378.72M over the last year.

Market cap
$3.38B
P/E ratio
None (reported a loss)
Annual sales
$378.72M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 17, 2026

Brands and businesses behind IOVA

  • Amtagvi: Generates revenue by selling a personalized cell therapy used to treat advanced melanoma after prior therapies fail.

IOVA’s flags, in plain English

Each flag is a number from Iovance Biotherapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.

Stupid Cash

Can pay this year's bills 5.2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 6% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 43.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Burning Cash

Losing money, profit margin of -58.2%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about IOVA

How big is Iovance Biotherapeutics?

Iovance Biotherapeutics’ market cap is $3.38B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $378.72M: what customers paid the company over the last year, before any costs.

What is IOVA’s P/E ratio?

IOVA has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with IOVA?

High manufacturing costs and long cell processing times constrain the number of patients the company can serve. That is one risk on Iovance Biotherapeutics’ card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Iovance Biotherapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. IOVA’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card